TRVITrevi Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $15.01 · now $15.01 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, TRVI has typically landed between $11.24 and $23.13 — a range of −25.1% to +54.1% from the issuance price $15.01.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,829 overlapping 1 month windows · 2019-05-072026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($15.01) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where TRVI has typically landed a month from the 2026-09-16 close of $15.01 — the range is history, not a prediction.

$11.24worst · -25.1%$23.13best · +54.1%
  • now $15.01 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $15.3 (+1.9%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $13.39$17.21
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $11.24$23.13
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,829 windows spanning 2019-05-07 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-02-28−67.1%−67.1%+0.0%
2020-02-27−58.2%−58.2%+0.0%
2020-02-21−57.1%−57.1%+6.7%
3 best
2022-02-22+367.1%−2.3%+373.5%
2022-02-18+345.1%−8.2%+345.1%
2022-02-24+328.6%+0.0%+355.1%

1,829 overlapping windows · 2019-05-072026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
57%
+6.2%
n=7
Feb
86%
+19.4%
n=7
Mar
57%
+29.7%
n=7
Apr
71%
+24.4%
n=7
May
14%
−10.6%
n=7
Jun
75%
+22.4%
n=8
Jul
38%
−1.4%
n=8
Aug
13%
−8.0%
n=8
Sep
25%
−7.0%
n=8
Oct
29%
−6.3%
n=7
Nov
29%
−4.6%
n=7
Dec
57%
+3.4%
n=7

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$20$7↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-03-25SCIASCIA THOMASofficerSale2,631 @ $6.60$17K−1.2% of holding+1.1%+12.6%221,373Form 4 · filed 1 day after the trade
2025-03-21GOOD JENNIFER LdirectorSale5,263 @ $6.58$35K−2.4% of holding+0.3%+13.2%213,313Form 4 · filed 4 days after the trade
2025-03-10Simon FarrelldirectorSale76,963 @ $6.73$518K−48.6% of holding−1.5%+22.0%81,250Form 4 · filed 2 days after the trade
2025-03-10Simon FarrelldirectorSale4,350 @ $7.15$31K−5.4% of holding−1.5%+22.0%76,900Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

50 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-03Colangelo DominickdirectorAward / grant35,00035,000Form 4
2026-06-03Heffernan Michael ThomasdirectorAward / grant35,00035,000Form 4
2026-06-03Mathers Edward TdirectorAward / grant35,00035,000Form 4
2026-06-03Meeker David PdirectorAward / grant35,00035,000Form 4
2026-06-03VANLENT ANNEdirectorAward / grant35,00035,000Form 4
2026-02-19SCIASCIA THOMASofficerAward / grant85,00085,000Form 4
2026-02-19Galletta ChristopherofficerAward / grant35,00035,000Form 4
2026-02-19Cassella James VofficerAward / grant215,000215,000Form 4
2026-02-19GOOD JENNIFER LdirectorAward / grant675,000675,000Form 4
2026-02-19Simon FarrelldirectorAward / grant160,000160,000Form 4
2026-01-08HASTINGS DAVID CdirectorAward / grant375,000375,000Form 4
2025-12-02Galletta ChristopherofficerOption exercise4,22526,095Form 4
2025-12-02Galletta ChristopherofficerOption exercise4,22515,775Form 4
2025-06-11Heffernan Michael ThomasdirectorAward / grant45,00045,000Form 4
2025-06-11Meeker David PdirectorAward / grant45,00045,000Form 4
2025-06-11VANLENT ANNEdirectorAward / grant45,00045,000Form 4
2025-06-11Colangelo DominickdirectorAward / grant45,00045,000Form 4
2025-06-11Mathers Edward TdirectorAward / grant45,00045,000Form 4
2025-05-31GOOD JENNIFER LdirectorAward / grant102,000156,400Form 4
2025-05-31Galletta ChristopherofficerAward / grant8,55013,110Form 4
2025-05-31SCIASCIA THOMASofficerAward / grant60,00092,000Form 4
2025-05-31Delfini LisaofficerAward / grant72,000110,400Form 4
2025-05-31Simon FarrelldirectorAward / grant72,000110,400Form 4
2025-03-25SCIASCIA THOMASofficerOption exercise2,631224,004Form 4
2025-03-25SCIASCIA THOMASofficerOption exercise2,6310Form 4
2025-03-21GOOD JENNIFER LdirectorOption exercise5,263218,576Form 4
2025-03-21GOOD JENNIFER LdirectorOption exercise5,2630Form 4
2025-03-10Simon FarrelldirectorOption exercise63,813126,963Form 4
2025-03-10Simon FarrelldirectorOption exercise17,50063,150Form 4
2025-03-10Simon FarrelldirectorOption exercise31,250158,213Form 4
2025-03-10Simon FarrelldirectorOption exercise17,5000Form 4
2025-03-10Simon FarrelldirectorAward / grant38,40038,400Form 4
2025-03-10GOOD JENNIFER LdirectorAward / grant54,40054,400Form 4
2025-03-10Galletta ChristopherofficerAward / grant4,5604,560Form 4
2025-03-10Simon FarrelldirectorOption exercise63,81311,187Form 4
2025-03-10Simon FarrelldirectorOption exercise31,25018,750Form 4
2025-03-10SCIASCIA THOMASofficerAward / grant32,00032,000Form 4
2025-03-10Delfini LisaofficerAward / grant38,40038,400Form 4
2025-02-18Delfini LisaofficerAward / grant225,500225,500Form 4
2025-02-18GOOD JENNIFER LdirectorAward / grant811,000811,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.